ADHD: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• LectureADHD

  Timothy E. Wilens

  An update on ADHD pharmacotherapy across the lifespan.

  Stimulants & ADHD Medications

MasterPsych Psychiatry Conference 2026

October 19–22, 2026 · Newport Beach, CA

• LectureADHD: with Multiple Comorbidities and Special Populations

  Steven R. Pliszka

  Managing ADHD when it co-occurs with other disorders or arises in special populations.

  Stimulants & ADHD Medications

• LectureADHD: Advanced Management Strategies

  Steven R. Pliszka

  Advanced medication strategies for ADHD beyond first-line stimulant trials.

  Stimulants & ADHD Medications

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• CourseUnderstanding and Managing Language Deficits in Pediatric Clinical Populations: Updates and Advances

  Theodore A. Petti · Stacy S. Drury · Mayank Gupta · Anthony Joseph Deo · Jennifer Zuk · Tyler Whitney · Gabrielle Blackman

  Institute on the frequently missed problem of language deficits in children with emotional, behavioral, and psychotic disorders, covering screening, neurobiology, comorbidity with ASD/ADHD, and referral for special education services.

  Autism & Neurodevelopmental DisordersChild & Adolescent

• SymposiumBefore the Diagnosis: Early Signals of Emerging ADHD

  Heather Marie Joseph · Sarah Karalunas · Marissa M. Dennis · Alexis Federico · Anastasia N. Kerr-German · Madelyn Heise

  Research symposium on prodromal markers of ADHD in early childhood, before formal diagnosis, drawing on developmental and neurocognitive cohort work.

  Child & Adolescent

• LectureLanguage Deficits as Critical Factors in Case Formulation and Treatment for ADHD in Children and Adolescents

  Mayank Gupta

  Explores how language deficits should inform case formulation and treatment of ADHD in youth.

  Child & Adolescent

• LectureManaging Inattention in ADHD, Autism, and Intellectual Developmental Disorder

  Olivia Hindera

  Addresses managing inattention across ADHD, autism, and intellectual developmental disorder.

  Autism & Neurodevelopmental DisordersChild & AdolescentStimulants & ADHD Medications

• LectureEarly Dyadic Interactions Between Caregivers and Infants at an Elevated Genetic Likelihood for ADHD

  Alexis Federico

  Explores caregiver-infant interactions in infants with elevated genetic likelihood for ADHD.

  Child & Adolescent

See all 135 adhd sessions at this meeting →

APNA 40th Annual Conference

October 28–31, 2026 · Phoenix, AZ

• WorkshopBeyond the Basics: Navigating Bias, Comorbidities, and Nuance in Adult ADHD

  Naomi Myrick

  Interactive clinical workshop preparing PMH-APRNs to recognize, evaluate, and manage adult ADHD, including diagnostic bias and comorbid conditions.

  Measurement-Based Care & Diagnosis

• LectureCo-Managing ADHD and Bipolar Disorder: An Update in Pharmacologic Treatment

  Kristen Munyan · Natalie Jones-Brown

  Mood-first medication sequencing approach for comorbid ADHD and bipolar disorder to reduce destabilization risk. Pharmacology-eligible.

  Bipolar DisorderStimulants & ADHD Medications

NEI Fall Congress 2026

November 5–8, 2026 · Colorado Springs, CO

• SymposiumI Still Haven't Found What I'm Looking For: Practical ADHD Management in Complex Cases

  Timothy E. Wilens

  Managing ADHD complicated by executive dysfunction and psychiatric comorbidity, with practical treatment-optimization tactics.

  Child & Adolescent

• SymposiumResidual Symptoms in ADHD: From Circuitry to Clinical Strategy

  Jeffrey Robert Strawn · Andrew J. Cutler

  Links residual ADHD symptoms to underlying circuitry and offers strategies to optimize treatment response.

  Neuroscience & MechanismsStimulants & ADHD Medications

• SymposiumADHD in Older Adults

  David W. Goodman

  Geriatric

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• PosterAssociation between Cannabis-Related Disorders and Incident Psychosis in Individuals with Adhd

  Christian Nolan

  Examines cannabis-related disorders and new psychosis among people with ADHD.

  Cannabis & CannabinoidsSchizophrenia & Psychosis

• PosterIs There a Relationship between Rising ADHD Diagnoses and Methamphetamine Use Patterns?

  Rachel Aniston

  Explores whether rising ADHD diagnoses relate to methamphetamine use patterns.

  Substance Use Disorders

NPA 32nd Annual Psychopharmacology Update 2027

February 10–13, 2027 · Las Vegas, NV

• LectureADHD and Substance Use in Women: Recognition, Risks, and Treatment Considerations

  Mariely Hernandez

  How ADHD and substance use intersect in women, with guidance on recognition, risk assessment, and treatment planning.

  Perinatal & Women's Mental HealthSubstance Use Disorders

• LectureUse of Digital Therapeutics in the Treatment of Children and Adults with ADHD

  Jeffrey H. Newcorn

  The evidence for digital therapeutics in ADHD and how they fit alongside medication across the lifespan.

  Digital Psychiatry & AI

Substance Use Disorders: A Comprehensive Review and Update 2027

February 15–17, 2027 · Lake Buena Vista, FL

• LectureADHD

  Timothy E. Wilens

  Discusses ADHD in relation to substance use risk and treatment.

  Substance Use Disorders

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• SymposiumS05 – Biomarker-based prediction and stratification in ADHD – where do we stand?

  Cristine Marie Yde Ohki · Carmen Schiweck · Barbara Franke · Marta Ribasés

  Microbiota metabolites, inflammation, epigenetics, and polygenic risk as candidate stratification biomarkers in ADHD.

  Inflammation & ImmunopsychiatryPharmacogenomics & Precision Psychiatry

• SymposiumS16 – Cutting edge neuromodulation methods in brain disorders: methods, mechanisms and personalised targeting

  Yvan Vachez · Katya Rubia · Odile van den Heuvel · Christine Reif-Leonhard

  DBS, trigeminal nerve stimulation in ADHD, rTMS-augmented exposure therapy for OCD, and implantable VNS for difficult-to-treat depression.

  Neuromodulation (ECT, TMS)OCD & Related DisordersTreatment-Resistant Depression

• LectureE07 – Long-term effects of ADHD medication: new evidence from real-world data

  Guido Biele · Kenneth Man

  Real-world evidence on long-term academic outcomes and the safety of methylphenidate in children.

  Child & AdolescentStimulants & ADHD Medications

WCP 2026 — 26th World Congress of Psychiatry

September 23–26, 2026 · Stockholm, Sweden

• CourseCourse 07: ADHD in Women - A Life Course Approach

  Prabha Chandra · Patricia van Wijngaarden · Parul Mathur

  Skills-based course on recognizing and managing ADHD in women across the lifespan.

  Perinatal & Women's Mental Health

• DebateDebate: ADHD - Adjunctive Stimulant for Depression Treatment – Pro-con?

  DepressionStimulants & ADHD Medications

• PlenaryPlenary Session 08: Mothers with ADHD. The Challenge of Raising Children when Diagnosed with ADHD

  Carolina Herrera-Ortiz

  Explores parenting challenges faced by mothers living with ADHD.

  Perinatal & Women's Mental Health

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• LectureADHD With Comorbidities: Anxiety, Mood Disorders, Autism, and Substance Use Disorders

  Timothy E. Wilens

  Frameworks for diagnostic clarification and treatment sequencing when ADHD co-occurs with anxiety, mood disorders, autism, or substance use, balancing symptom control against misuse and destabilization risks.

  Anxiety DisordersAutism & Neurodevelopmental DisordersSubstance Use Disorders

• SymposiumFirst-Line Decisions: Lifestyle Modification or Medication? Balancing Pharmacologic and Non-Pharmacologic Care in ADHD

  James Greenblatt · Julie Carbray

  Guides initial ADHD treatment choices between stimulant/non-stimulant medication and behavioral, coaching, and environmental strategies based on severity, preference, and comorbidity.

  Lifestyle & Integrative PsychiatryStimulants & ADHD Medications

• SymposiumMasterClass: Features Out of Focus: Recognition and Treatment of Emotional Dysregulation and Executive Dysfunction in ADHD

  Gregory Mattingly · Julie Carbray

  Highlights emotional dysregulation and executive dysfunction as underrecognized drivers of ADHD impairment, with neurobiological context and emerging pharmacologic options.

  Stimulants & ADHD Medications

• SymposiumPractical Management of Autism and Co-Occurring Psychiatric Conditions

  Kristin Sohl · Jo Hughes

  Integrated framework for assessing and treating anxiety, ADHD, and mood disorders in autistic children, including evidence-based medication use, behavioral therapy, and family engagement.

  Anxiety DisordersAutism & Neurodevelopmental DisordersChild & Adolescent

• SymposiumWomen, Hormones, and ADHD: What We Know, What We Don't, and What Clinicians Need to Understand

  Gregory Mattingly · Moushumi Mukerji

  Evidence-informed overview of how estrogen and progesterone shifts across the menstrual cycle, pregnancy, and perimenopause affect attention, mood, and stimulant response, with prescribing considerations amid research gaps.

  Perinatal & Women's Mental HealthStimulants & ADHD Medications

See all 6 adhd sessions at this meeting →